首页> 美国卫生研究院文献>EMBO Reports >Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?
【2h】

Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?

机译:干扰有丝分裂进行抗癌治疗:细胞死亡是唯一的答案吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Interfering with mitosis for cancer treatment is an old concept that has proven highly successful in the clinics. Microtubule poisons are used to treat patients with different types of blood or solid cancer since more than 20 years, but how these drugs achieve clinical response is still unclear. Arresting cells in mitosis can promote their demise, at least in a petri dish. Yet, at the molecular level, this type of cell death is poorly defined and cancer cells often find ways to escape. The signaling pathways activated can lead to mitotic slippage, cell death, or senescence. Therefore, any attempt to unravel the mechanistic action of microtubule poisons will have to investigate aspects of cell cycle control, cell death initiation in mitosis and after slippage, at single‐cell resolution. Here, we discuss possible mechanisms and signaling pathways controlling cell death in mitosis or after escape from mitotic arrest, as well as secondary consequences of mitotic errors, particularly sterile inflammation, and finally address the question how clinical efficacy of anti‐mitotic drugs may come about and could be improved.
机译:干扰有丝分裂用于癌症治疗是一个古老的概念,在临床上已被证明非常成功。自20多年来以来,微管毒药一直用于治疗患有不同类型的血液或实体癌的患者,但是这些药物如何达到临床反应仍不清楚。至少在皮氏培养皿中,有丝分裂阻滞细胞可以促进其死亡。然而,在分子水平上,这种类型的细胞死亡定义不清,癌细胞经常找到逃逸的方法。激活的信号通路可导致有丝分裂滑移,细胞死亡或衰老。因此,任何试图解开微管毒物机理的尝试都必须以单细胞分辨率研究细胞周期控制,有丝分裂中的细胞死亡起始以及滑移后的死亡。在这里,我们讨论了控制有丝分裂中或逃脱有丝分裂阻滞后细胞死亡的可能机制和信号传导途径,以及有丝分裂错误(尤其是无菌炎症)的继发性后果,最后讨论了抗有丝分裂药物的临床功效如何产生并可以改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号